Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of quinazolines. Its structure features a quinazolinone core substituted with an 8-methyl group and a propyl chain linked to a dihydropyridine ring bearing a para-fluorophenyl substituent. It has been studied as an experimental agent and is known to act as an inhibitor of poly [ADP-ribose] polymerase 1 (PARP1), with reported IC50 values in the low nanomolar range. PARP inhibitors are being explored for their potential in cancer therapy due to their role in DNA repair inhibition[2][4]. There is no evidence that this compound has reached clinical development or approval.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-{3-[4-(4-fluorophenyl)-3,6-dihydro-1(2h)-pyridinyl]propyl}-8-methyl-4(3h)-quinazolinone.